Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Immatics Announces Third Quarter 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11...
Nasdaq GlobeNewswire
17/11/2025
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera®…
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysisZiihera plus Tevimbra® (tislelizumab)and chemotherapydemonstrated clinically meaningful and statistically significant improvements in OS and PFS versus trastuzumab and chemotherapyResults support Ziihera’s...
Nasdaq GlobeNewswire
17/11/2025
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment…
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen 1 Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages 2 CAMBRIDGE, Mass., Nov.17, 2025(GLOBE NEWSWIRE) --Biogen Inc.(Nasdaq: BIIB) today announced the Committee for Medicinal...
Nasdaq GlobeNewswire
17/11/2025
Krinwave Expands Boundaries of Medical Imaging Using NVIDIA Jetson Thor
The system also breaks the diffraction limit to achieve super-resolution imaging, enabling high-definition visualization of adult cranial structures and propelling ultrasound imaging into a new era of super-resolution, precision, and intelligent diagnostics This leap in performance is enabled by NVIDIA's full-stack edge computing platform, including Jetson Thor. Kirinwave developers leveraged NVIDIA acceleration tools such as Nsight Profiler, NVIDIA CUDA, NVIDIA TensorRT, and NVIDIA JetPack to…
PR Newswire
17/11/2025
Fapon at MEDICA 2025: AI-Driven Breakthroughs in Diagnostic Solutions, Featuring…
Fapon is also showcasing its one-stop IVD solutions that include IVD raw materials, reagent services, and open-system instruments. Among these, the chemiluminescence one-stop solution stands out, leveraging high-performance core raw materials, a panel of over 70 self-developed assays, and the flexible Shine i-Series CLIA analyzers covering low to ultra-high throughput to precisely meet testing needs across various scenarios. Notably, Fapon's Shine mT8000 Fully Automatic Clinical Chemistry and…
PR Newswire
17/11/2025
Ozelle Launches Next-Generation AI + Complete Blood Morphology Solution at…
Developed to meet the growing demand for rapid and standardized testing, the solution introduces three key breakthroughs: Developed to meet the growing demand for rapid and standardized testing, the solution introduces three key breakthroughs: Beyond product innovation, Ozelle continues to build an intelligent diagnostic ecosystem where hematology, biochemistry, and immunology data converge under a unified AI framework — transforming fragmented workflows into continuous, data-driven care...
PR Newswire
17/11/2025
Zelluna ASA: New share capital registered
Oslo, Norway, 17 November, 2025:Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new shares (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in the retail offering carried out via the PrimaryBid platform (the "Retail…
Nasdaq GlobeNewswire
17/11/2025
Interlinked advances to next phase - CE-MDR approved dual-use solution for…
"This is a strategic step for Interlinked. The fact that ReLink® can deliver high safety and functionality in both civilian care and field hospital environments demonstrates the strength of our platform. Our ambition is to promote patient safety – whether care is delivered at a major university hospital or in an emergency preparedness situation. The need is clear, and interest is growing rapidly," says Katarina Hedbeck, CEO and co-founder of Interlinked AB. "This is a strategic…
PR Newswire
17/11/2025
Glow This Winter: COSRX Reveals Unmissable Deals for Amazon Black Friday & Cyber…
Exclusive Sets, Unbeatable DealsFor Amazon Black Friday and Cyber Monday 2025, COSRX introduces exclusive Peptide and Snail value sets — combining two bestsellers, The 6 Peptide Skin Booster Serum and The Advanced Snail 96 Mucin Power Essence, and innovations at their most irresistible prices. Exclusively on Amazon, these glow-restoring essentials bring professional-level care and visible radiance to your winter skincare routine. Exclusive Sets, Unbeatable DealsForAmazon Black Friday and...
PR Newswire
17/11/2025
Cardiovalve Submits CE File for Approval Following Successful TARGET Study…
The TARGET Study Interim Results: "Safety and Performance of the Cardiovalve Replacement System for Tricuspid Regurgitation" were presented yesterday by Prof. Georg Nickenig, on behalf of the TARGET study investigators, during the Top Late-Breaking Trials session at PCR London valves Main Arena. The TARGET Study Interim Results : "Safety and Performance of the Cardiovalve Replacement System for Tricuspid Regurgitation" were presented yesterday by Prof.Georg Nickenig, on…
PR Newswire
17/11/2025
Ramsay Sante : conditions of availability and consultation of the preparatory…
PRESS RELEASE Paris, 14 thNovember 2025COMBINED GENERAL MEETING OF DECEMBER 11, 2025 Conditions of availability and consultation of the preparatory documents for the Ramsay Générale de Santé General Meeting of December 11, 2025 The shareholders of Ramsay Générale de Santé are invited to participate in the Combined General Meeting on Thursday, December 11, 2025, which will take place at 10 a.m. at the Apostrophe 83 avenue Marceau 75116 Paris.The...
Nasdaq GlobeNewswire
17/11/2025
Clue Expands Wearable Integrations with Withings, Ultrahuman, WHOOP, Huawei…
Clue , the #1 women-led period and cycle tracker trusted by over 100 million worldwide, has today announced expanded integrations with leading wearable partners Withings , Ultrahuman , WHOOP,Huawei , Polar , Fitbit , Luna and Noise - giving women and people with cycles access to a richer picture of their health. These new partnerships follow Clue’s existing relationship with ŌURA , which has been in place in 2023, and are part of the brand’s continued mission...
Nasdaq GlobeNewswire
17/11/2025
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of…
Daix (France), New York City (New York, United States), November 17, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), today announced that the underwriters of the previously announced public offering in the United States (the " Offering ") of 38,961,038…
Nasdaq GlobeNewswire
17/11/2025
TME Pharma announces receipt of agreements in principle to extend certain bond…
TME Pharma announces receipt of agreements in principle to extend certain bond agreementsBerlin, Germany , November 17, 2025, 08.00am CET–TME Pharma N.V. (Euronext Growth Paris: ALTME),a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period. These bond...
Nasdaq GlobeNewswire
17/11/2025
ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication…
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)US FDA clearance now allows use of the ARC-EX ®System both in clinicsandhomesARC-EX is the first and only FDA-cleared technology demonstrated to improve hand strength and sensation in people with spinal cord injuryYear to date, ARC-EX Systems have been purchased by more than 60 US clinics EINDHOVEN, the Netherlands, Nov.17, 2025...
Nasdaq GlobeNewswire
17/11/2025
CFO Tania Micki to leave Tecan for new role in 2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, November 17, 2025 –The Tecan Group (SIX Swiss Exchange: TECN) today announced that Tania Micki, Chief Financial Officer and member of the Management Board since February 2020, will be leaving the company to pursue an external opportunity. She will continue in her role through May 2026 to ensure a smooth transition. Tecan will nominate her successor in due time, leveraging...
Nasdaq GlobeNewswire
17/11/2025
LG DEBUTS SKS CHICAGO SHOWROOM, OFFERING AN IMMERSIVE LUXURY LIFESTYLE…
The SKS Chicago Showroom is an innovation hub where visitors can experience SKS's "True to Food" philosophy and advanced technologies in an immersive, lifestyle-oriented setting. Located inside THE MART (formerly the Merchandise Mart) – one of North America's premier destinations for kitchen and interior design professionals – the showroom helps designers, builders and consumers imagine how the latest SKS solutions can enrich modern living with style and simplicity. The SKS Chicago…
PR Newswire
17/11/2025
China's Dialysis Industry Leader to Showcase Cutting-Edge Solutions at MEDICA…
At MEDICA, visitors will have the opportunity to explore the SWS's comprehensive product portfolio, designed to improve treatment outcomes and workflow efficiency. Highlights include: At MEDICA, visitors will have the opportunity to explore the SWS's comprehensive product portfolio, designed to improve treatment outcomes and workflow efficiency. Highlights include: Based inChongqing, SWS Medical, is a prominent global provider of innovative medical products and services. Its offerings...
PR Newswire
17/11/2025
Fotona Appoints Aimee Desrosiers as Global Chief Marketing Officer
Prior to that, Desrosiers has also held senior leadership roles including Chief Revenue Officer & President of Medical Aesthetics at The SEES Group, Chief Marketing Officer at Nvision, and Senior Vice President with Masco Coatings. In these roles, she built scalable consumer and professional marketing models, introduced digital and direct-to-consumer programs, and drove sustained revenue and brand growth across competitive healthcare markets. Prior to that, Desrosiers has also held senior...
PR Newswire
16/11/2025
Biogen Completes Acquisition of Alcyone Therapeutics
Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system.ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people...
Nasdaq GlobeNewswire
14/11/2025
CROSSJECT completes €5 million financing with Vatel Capital
Press releaseCROSSJECTcompletes €5 million financing with Vatel CapitalDIJON, France – November 14th, 2025 (8.30 PM CET) –CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, in the advanced stages of development and registration of ZEPIZURE®, an injectable for the treatment of epileptic seizures, today announces the completion of a...
Nasdaq GlobeNewswire
14/11/2025
Positioning Barbados as the Caribbean’s Life Sciences Hub
EarlyHealth City to Anchor US$200 Million Investment Located across 45 acres, EarlyHealth City will feature three domes totaling more than 250,000 square feet of contract manufacturing space dedicated to the production of oral solids, semi-solids, liquids, and advanced biologics. This includes integrated capabilities for cell cultivation, upstream and downstream bioprocessing, and full scale-up to commercial release under United States and European Union Good Manufacturing Practice (GMP)...
Nasdaq GlobeNewswire
14/11/2025
Fagron completes share buy-back program
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its owns shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00. A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of...
Nasdaq GlobeNewswire
14/11/2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES PRESS RELEASE REGULATED INFORMATION 14 November 2025, 6:00 pm CETGhent, Belgium, 14 November 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS (" GEM...
Nasdaq GlobeNewswire
14/11/2025
Altri Comunicati
